

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00455)

CHANGE OF AUDITORS

This announcement is made by the board (the **Board**) of directors (the **Director(s)**) of Tianda Pharmaceuticals Limited (the **Company**) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Resignation of Auditor

The Board of the Company announces that Messrs. Deloitte Touche Tohmatsu, Certified Public Accountants (**Deloitte**), having taken into account many factors including the level of audit fees and the proposed scope of work covered, resigned as the auditor of the Company and its subsidiaries (collectively, the **Group**) with effect from 12 October 2017. Deloitte has confirmed in its letter of resignation that from Deloitte's perspective there is no matter in connection with its resignation that needs to be brought to the attention of the shareholders (**Shareholders**) and creditors of the Company. The Board and the audit committee of the Company (the **Audit Committee**) have confirmed that there are no disagreements or unresolved matters between the Company and Deloitte, and that they are not aware of any matter in connection with the resignation of Deloitte that needs to be brought to the attention of the Shareholders or creditors of the Company.

Deloitte has been auditor of the Group for more than 20 financial years, the Board would like to take this opportunity to express its sincere gratitude to Deloitte for its professional services rendered to the Company in the past years.

Appointment of Auditor

The Audit Committee proposes to appoint Messrs. Ernst & Young, Certified Public Accountants (**EY**) as the auditor of the Group (the **Proposed Appointment**) to fill the casual vacancy following the resignation of Deloitte, and to hold office until the conclusion of the next annual general meeting of the Company. EY is currently undergoing certain internal procedures in relation to the Proposed Appointment. The Company will make further announcement once the appointment is made.

In reaching the decision for the change of auditors, the Board and the Audit Committee have taken into account the efficiency of the audit services, the proposed scope of work covered and the fee quotation. The Board also considers that for good corporate governance practices, the change of auditors will help enhance the effectiveness of the internal control of the Group and keep the Group accountable to a high level of accounting scrutiny. The Board is of the view that the Proposed Appointment of EY as the best interests of the Company and its Shareholders as a whole.

For and on behalf of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 13 October 2017

As at the date of this announcement, the executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive Directors are Mr. SHEN Bo, Mr. FENG Quanming and Mr. SHI Shaobin; and the independent non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Mr. CHIU Fan Wa.